OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer
Go back to OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer| OncoSec Medical Incorporated (NASDAQ: ONCS) | Delayed: 0.28 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.28 | 52 Week High | $3.49 | |||
| Open | $9.81 | 52 Week Low | $1.36 | |||
| Day High | $0.28 | P/E | N/A | |||
| Day Low | $0.28 | EPS | $-0.04 | |||
| Volume | 127 | |||||
